Mylan is allying with Biocon for the development, manufacturing, supply, and commercialization of multiple generic biologic compounds for the global marketplace. The companies will share development and certain other costs related to bringing the products to market.
Mylan will have exclusive commercialization rights in the U.S., Canada, Japan, Australia, New Zealand, the EU, and European Free Trade Association countries (Iceland, Liechtenstein, Norway, and Switzerland) through a profit-sharing arrangement. Mylan will have co-exclusive commercialization rights with Biocon in all other markets around the world.
“This unique collaboration combines Biocon's scientific expertise, excellent product development track record, appreciation of complex regulatory requirements, and state-of-the-art, cost-efficient, and scalable biologics manufacturing with Mylan's one-of-a-kind global commercial footprint and our regulatory expertise around the world,” notes Mylan's chairman and CEO, Robert J. Coury.
“Generic biologics, especially monoclonal antibodies, are expected to become the next great bolus of growth in the generic pharmaceutical industry, and through this alliance, Mylan and Biocon have covered all four corners of what any organization would want or need to have secured to offer a highly competitive and distinct generic biologics product portfolio with tremendous growth potential for the coming decade.”
Abraxis Obtains North American and EU Rights to Biocon’s G-CSF Biosimilar (July 20, 2007)
Novozymes Acquires Part of Indian Company Biocon for about $116M (July 18, 2007)
Invitrogen Taps Biocon for Insulin Supply to the Global Cell Culture Market (July 18, 2007)
Mylan Bags Merck Generics with $6.6B Bid (May 14, 2007)
Pfizer Can Assert Only One of Two Patents in Litigation Against Mylan (Oct. 19, 2006)